Dutasteride was patented in 1996  and was first described in the scientific literature in 1997.  It was approved by the FDA for the treatment of BPH in November 2001 and was introduced into the . market the following year under the brand name Avodart.  Dutasteride has subsequently been introduced in many other countries as well, including throughout Europe and South America .  The patent protection of dutasteride expired in November 2015 and the drug has since become available in the . in a variety of low-cost generic formulations . 
DHT is a potent agonist of the AR, and is in fact the most potent known endogenous ligand of the receptor. It has an affinity (K d ) of to nM for the human AR, which is about 2- to 3-fold higher than that of testosterone (K d = to nM)  and 15–30 times higher than that of adrenal androgens .  In addition, the dissociation rate of DHT from the AR is 5-fold slower than that of testosterone.  The EC 50 of DHT for activation of the AR is nM, which is about 5-fold stronger than that of testosterone (EC 50 = nM).  In bioassays , DHT has been found to be - to 10-fold more potent than testosterone.